Cardiff Oncology, Inc. · NASDAQ:CRDF
Cardiff Oncology — Q3 2023 Earnings Presentation
10 slides from Cardiff Oncology's earnings presentation, Nov 1, 2023
Slide 1: Q3 2023 Financial Results and Business Update
Q3 2023 Financial Results and Business Update
Slide 2: Forward-looking statements
Forward-looking statements CERTAIN STATEMENTS IN THIS PRESENTATION ARE FORWARD-LOOKING within the meaning of the Private Securities Litigation Reform Act of 1995, These statements may be identified by the use of words such as “anticipate,” "believe," "forecast," "estimated" and "intend" or other sim
Slide 3: August data release, September data release
August data release • • • September data release • •
Slide 4: Onvansertib's clinical signal of efficacy and tolerability
1. Onvansertib’s clinical signal of efficacy and tolerability 2. Onvansertib’s novel approach to PLK1 inhibition 3. Onvansertib can combine with 1st / 2nd line SoC regimens that target large populations 4. Third party support and validation including FDA, Pfizer 5. Strong financial position with cas
Slide 5: Cardiff Oncology is focused on three objectives to create value
Cardiff Oncology is focused on three objectives to create value 1. Lead program: RAS-mut mCRC 2. Earlier-stage programs: Pancreatic, SCLC, TNBC 3. Pipeline expansion: Preclinical programs Generate data from the 1% line RAS-mutated mCRC CRDF-004 trial in mid-2024 Develop through investigator-initiate
Slide 6: Lead program: RAS-mut mCRC
Cardiff Oncology is focused on three objectives to create value 1. Lead program: Generate data from the 1* line RAS-mutated mCRC RAS-mut mCRC CRDF-004 trial in mid-2024 Phase 1b/2 data from 2°¢ line KRAS-mut mCRC — 73% ORR in bev naive patients vs. ~25% for historical controls - 15-month median PFS
Slide 7: Earlier-stage programs and pipeline expansion
Cardiff Oncology is focused on three objectives to create value 2. Earlier-stage programs: Pancreatic, SCLC, TNBC Develop through investigator-initiated trials 3. Pipeline expansion: Conduct preclinical studies of new combinations and Preclinical programs indications
Slide 8: Relative Tumor Volume
• • BC1117 BC1080 Relative Tumor Volume
Slide 9: We expect clinical data from our 1st line RAS-mutated mCRC trial in mid-2024
We expect clinical data from our 1st line RAS-mutated mCRC trial in mid-2024
Slide 10: Onvansertib's clinical signal of efficacy and tolerability
1. Onvansertib’s clinical signal of efficacy and tolerability 2. Onvansertib’s novel approach to PLK1 inhibition 3. Onvansertib can combine with 1st / 2nd line SoC regimens that target large populations 4. Third party support and validation including FDA, Pfizer 5. Strong financial position with cas